Mitochondrial respiratory chain (MRC) consists of the protein complexes I, II, III, IV, and V to carry oxidative phosphorylation (OXPHOS), which depends on electron transport to generate ATP. Electron "leakage" from MRC generates reactive oxygen species (ROS). Chronic myeloid leukemia in chronic phase (CML-CP) stem cells (LSCs) produce high levels of mitochondrial ROS causing oxidative DNA damage resulting in genomic instability generating imatinibresistant BCR-ABL1 kinase mutants and additional chromosomal aberrations. Using global mRNA microarray analysis combined with Ingenuity pathway analysis we found that LSCs display enhanced expression of genes encoding MRC complexes I, II, IV, and V. However, expression of genes encoding complex III was deregulated. Treatment with imatinib did not correct the aberrant levels of MRC genes. Therefore we postulate that abnormal expression of MRC genes may facilitate electron "leakage" to promote production of ROS and accumulation of genomic instability in LSCs in imatinib-naive and imatinib-treated patients.
Introduction
Chronic myeloid leukemia in chronic phase (CML-CP) is initiated by the oncogenic BCR-ABL1 tyrosine kinase that transforms hematopoietic stem cells (HSCs) to leukemia stem cells (LSCs) [1] . Deregulated growth of LSCs-derived leukemia progenitor cells (LPCs) leads to the manifestation of the disease. ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib and nilotinib may induce favorable therapeutic responses, but LSCs are intrinsically insensitive to TKIs despite inhibition of BCR-ABL1 kinase [2] . CML-CP cells may at some stage acquire additional genetic changes that confer TKI resistance and induce more aggressive CML blast phase (CML-BP) [3] .
Genomic instability may result from enhanced oxidative DNA damage caused by reactive oxygen species (ROS) [4] . Superoxide anion (•O 2 -), the first produced ROS molecule, is a moderately stable free radical. Superoxide dismutase uses •O 2 -to generate hydrogen peroxide (H 2 O 2 ), which may be then converted to the highly reactive hydroxyl group (•OH). ROS can damage DNA bases to produce oxo-derivatives such as 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxoG) and also induce spontaneous DNA double-strand breaks (DSBs).
Unfaithful and/or inefficient repair of these oxidative DNA lesions can generate point mutations and chromosomal aberrations.
We reported recently that CML-CP LSCs and early LPCs accumulate high levels of ROS resulting in accumulation of TKI-resistant BCR-ABL1 kinase mutants and additional chromosomal aberrations [5] . This effect was due to Rac2-mediated modification of the mitochondrial membrane potential (∆Ψ m ) associated with slower electron flow through mitochondrial respiratory chain (MRC) complex III. This phenomenon facilitated electron "leakage" from the complex III and production of superoxide anion. The current study suggests that an imbalance in the expression of MRC components may contribute to production of ROS in CML-CP LSCs. These results were visualized using dot plots where the average expression of all genes in that functional group is represented as a single dot. The average expression is plotted on a log2
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scale on the y axis, and each subpopulation in each disease state on the x axis.
Analysis of CML-CP samples treated or not with imatinib: CML-CP patient samples, imatinib treatment and microarray analysis were as described before [6] . Briefly, CML Expression data were normalized with the robust multiarray average (RMA) algorithm, with background adjustment, quantile normalization, and median polish summarization. Probe sets with low expression levels or low variability across samples were filtered. For genes with multiple probe sets, the gene level expression was set to be the median of the probe sets.
Linear regression was used to model the gene expression with the consideration of 2 3 2 factorial design and matched samples. Differentially expressed genes were identified by calculating empirical Bayes moderated t-statistic, and p values were adjusted by FDR with the ''LIMMA'' package. Gene Set Enrichment Analysis (GSEA) was performed with GSEA software version 2.04 (http://www.broadinstitute.org/gsea/) for detection of enrichment of predetermined gene sets with t-scores from all 13,812 genes [7] . These lists were uploaded directly into IPA software (Ingenuity Systems).
Results
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Discussion
Some cancer stem cells (CSCs), for example breast and lung CSCs, maintain low ROS levels due to several factors, including increased expression of free radicals scavengers, lower quantity of mtDNA and higher ∆Ψ m [8, 9] . In contrast, LSCs from BCR-ABL1 -positive CML-CP and IDH1/2 mutation -positive AML accumulate high levels of ROS [5, 10] . We reported that high levels of ROS in CML-CP LSCs induced oxidative DNA damage resulting in genomic instability which may produce imatinib-resistant BCR-ABL1 kinase mutants and additional chromosomal aberrations leading to the disease relapse and/or malignant progression [5, 11, 12] .
Since CML-CP LSCs, in particular the quiescent sub-population, are refractory to TKIs, genomic instability in these cells is especially dangerous [13] . Identification of the mechanisms of genomic instability in CML-CP LSCs may lead to novel therapeutic modalities preventing the disease relapse/malignant progression in patients under TKI treatment.
At least 50% of ROS in CML-CP LSCs is produced by mitochondria [5] . However, the mechanism responsible for this phenomenon has not been described. Here we report that CML-CP display deregulated expression of the MRC components, which may contribute to overproduction of mitochondrial ROS. Numerous MRC genes appear overexpressed in LSCs suggestimg enhanced OXPHOS, which may reflect enhanced proliferation associated with decreased self-renewal and increased differentiation of LSCs in comparison to normal HSCs [14] . Unexpectedly, two members of MRC complex III, UQCRB and CTYB were downregulated.
The reason for this effect is not known, but it may result from transcriptional regulation and/or better adaptation to bone marrow niche conditions [15] [16] [17] . Overall, elevated or normal expression of the components of MRC complex I and II suggests that OXPHOS reaction and electron flow can be properly initiated, but deregulated expression of the members of MRC complex III may "derail" and/or slow down the flow of electrons causing their "leakage". This speculation is supported by our previous report that Rac2-mediated reduction of ∆Ψ m combined with inhibition of the electron flow through MRC complex III facilitated electron "leakage" resulting in high levels of ROS in CML-CP [5] .
We reported before that imatinib inhibited BCR-ABL1 kinase and ROS in BCR-ABL1 -positive 32Dcl3 cell line [12] . However, despite inhibition of BCR-ABL1 kinase, imatinib did not Overall, our findings are consistent with the hypothesis that mitochondria present in CML-CP LSCs display a unique "metabolic-bioenergetic-oxidative" phenotype in which dysfunctional MRC generates high levels of mitochondrial ROS and low levels of ATP; the latter effect being compensated by enhanced glucose uptake and aerobic glycolysis [18] . CML-CP progression to CML-BP was accompanied with extensive downregulation of the components of MRC complex I and IV suggesting more pronounced defect. 
